Mutation Specific Kinase activity Measurements
Profiling Kinase Conformations
KinCon biolabs is a biotech startup based in Innsbruck Austria.
We are creating unique biosensors for improved kinase-inhibitor development.
The luciferase based KinCon biosensor measures drug-driven effects on kinase-activity by reflecting changes of cellular kinase conformations.
This technology allows reliable profiling of potential kinase inhibitors under physiological conditions:
- Direct measurement in living cells
- Cancer drug profiling in real-time
- Simple integration of patient mutations for precision medicine
Our vision is to improve drug development of kinase-targeted drugs through mutation-specific activity profiling with our live-cell biosensor platform.
Team
Meet the people working to provide you with new tools to assess kinase drug efficacy.
Eduard Stefan
CEO| Co-Founder
Philipp Tschaikner
CSO | co founder
Alexandra Fritz
Lab Assistant
Publications
Recent Publications in which the KinCon technology is applied
Science Signaling, April 2021
DOI: 10.1126/scisignal.abe4509
IUBMB Life, February 2020
DOI: 10.1002/iub.2241
Science Advances, August 2019
DOI: 10.1126/sciadv.aav8463
Contact Us
KinCon biolabs GmbH is a University of Innsbruck spin-off company supported by funding from the Austrian Research Promotion Agency (FFG) Spin-off Fellowship and Austria Wirtschaftsservice (AWS) Preseed program.
